Oxytocin Injection Recalled for Current Good Manufacturing Practice Violations
Fresenius Kabi Compounding is voluntarily recalling over 4,400 bags of Oxytocin 0.9% Sodium Chloride Injection due to current Good Manufacturing Practice violations. No illnesses have been reported.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II recall initiated voluntarily by the manufacturer for current Good Manufacturing Practice violations. No illnesses, injuries, or hospitalizations have been reported. The hazard is a manufacturing process deficiency rather than confirmed contamination, qualifying this as a precautionary recall.
Plain-English summary
Fresenius Kabi Compounding, LLC is recalling Oxytocin 0.9% Sodium Chloride Injection USP (30 units per 500 mL) due to current Good Manufacturing Practice (cGMP) violations. The recall affects 4,436 bags distributed to 125 direct accounts nationwide. Affected lot numbers are C274-000038801 (expiration 9-Oct-24), C274-000039045 (expiration 24-Oct-24), and C274-000039240 (expiration 31-Oct-24). The manufacturer voluntarily initiated the recall on September 25, 2024; the FDA classified it as Class II on October 21, 2024.
No illnesses or injuries have been reported in connection with this product. Healthcare providers and patients with this product should contact the manufacturer for guidance.
The recalled product
- Product
- Oxytocin 0.9% Sodium Chloride Injection USP, 30 units per 500 mL Single Dose Bag, Rx only, Fagron Sterile Services, Canton, MA NDC: 71506-028-59
- Manufacturer
- Fresenius Kabi Compounding, LLC
- Category
- Drug — Injectable Medication
- Hazard
- cgmp-violation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lot # C274-000038801
- exp. date 9-Oct-24 C274-000039045
- exp. date 24-Oct-24 C274-000039240
- exp. date 31-Oct-24
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- HighBeak & Skiff Alcohol Antiseptic Sanitizer recalled for acetaldehyde contamination
FDA (Drugs) · 2026-06-17
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- SevereCIMZIA injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-05-27